TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06316297

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Acne mRNA vaccine
Description: Pharmaceutical form:Liquid suspension for injection-Route of administration:intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Acne mRNA vaccine
Description: Pharmaceutical form:Liquid suspension for injection-Route of administration:intramuscular

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form:Liquid solution for injection-Route of administration:intramuscular
Study: NCT06465277

Intervention type: DIAGNOSTIC_TEST
Intervention: Dobutamine stress CMR
Description: Dobutamine stress testing will be undertaken in keeping with local departmental clinical guidelines with a graded increase in dobutamine infusion up to a maximum of 10microgram/kg/min. The patients' medications will be managed in keeping with the usual clinical practice and departmental guidelines.~At rest and on each graded level of dobutamine infusion we will collect cine loops of the cardiac cycle including a short-axis stack of the ventricles, a four-chamber view and flow imaging perpendicular to the main, left and right pulmonary arteries.~Post-processing will be dual reported by blinded observers using the Argus analysis software (Siemens) according to a standardised protocol. A safety report of each CMR scan will be generated by a consultant cardiologist, any abnormalities identified will be referred to the appropriate medical speciality and highlighted to the patient's clinical team.

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac biomarker sample
Description: blood samples will be collected pre-operatively, in recovery, on post-operative days 1 and 2, and at 4-8 weeks post-operatively

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac biomarker sample
Description: blood samples will be collected pre-operatively, in recovery, on post-operative days 1 and 2, and at 4-8 weeks post-operatively

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac biomarker sample
Description: blood samples will be collected pre-operatively, in recovery, on post-operative days 1 and 2, and at 4-8 weeks post-operatively
Study: NCT05425641

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Action Planning
Description: Individuals will receive daily text messages that include the Action Planning behavior change technique (BCT) with the goal of increasing daily walking by 1,000 more steps than their baseline average step count. An example of the Action Planning BCT is Take one minute and plan for today how, where and when you can walk an extra 1,000 steps more than your baseline average. Have you planned for today?

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Action Planning
Description: Individuals will receive daily text messages that include the Action Planning behavior change technique (BCT) with the goal of increasing daily walking by 1,000 more steps than their baseline average step count. An example of the Action Planning BCT is Take one minute and plan for today how, where and when you can walk an extra 1,000 steps more than your baseline average. Have you planned for today?

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Action Planning
Description: Individuals will receive daily text messages that include the Action Planning behavior change technique (BCT) with the goal of increasing daily walking by 1,000 more steps than their baseline average step count. An example of the Action Planning BCT is Take one minute and plan for today how, where and when you can walk an extra 1,000 steps more than your baseline average. Have you planned for today?
Study: NCT04658147

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 480mg will be administered as a 30 minute IV infusion (-/+15min) at cycle 1 day 1 and at cycle 2 day 1 (28 days) then every month for up to 12 months. Intravenous administration of Nivolumab (480 mg) will occur on Cycle 1 and 2 of the study then every 28 days up to a year. Nivolumab will be administered on Day 1 of each cycle for 10 doses/ months (whichever occurs first) for adjuvant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 480mg will be administered as a 30 minute IV infusion (-/+15min) at cycle 1 day 1 and at cycle 2 day 1 (28 days) then every month for up to 12 months. Intravenous administration of Nivolumab (480 mg) will occur on Cycle 1 and 2 of the study then every 28 days up to a year. Nivolumab will be administered on Day 1 of each cycle for 10 doses/ months (whichever occurs first) for adjuvant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relatlimab
Description: Patients will receive 480 mg Relatlimab intravenously (-/+15min) on cycle 1 day 1 and at cycle 2 day 1 (every 28 days) for up to 1 year co-administered with Nivolumab.
Study: NCT04752215

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 765049
Description: BI 765049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 765049
Description: BI 765049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ezabenlimab
Description: ezabenlimab
Study: NCT05425641

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Action Planning
Description: Individuals will receive daily text messages that include the Action Planning behavior change technique (BCT) with the goal of increasing daily walking by 1,000 more steps than their baseline average step count. An example of the Action Planning BCT is Take one minute and plan for today how, where and when you can walk an extra 1,000 steps more than your baseline average. Have you planned for today?

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Action Planning
Description: Individuals will receive daily text messages that include the Action Planning behavior change technique (BCT) with the goal of increasing daily walking by 1,000 more steps than their baseline average step count. An example of the Action Planning BCT is Take one minute and plan for today how, where and when you can walk an extra 1,000 steps more than your baseline average. Have you planned for today?
Study: NCT05553145

Intervention type: DIAGNOSTIC_TEST
Intervention: Autoimmune Antibody Assays
Description: GAD-65, Islet cell-Ab, IA-2 Ab, anti-insulin Ab, and ZnTn8 Ab

Intervention type: DIAGNOSTIC_TEST
Intervention: Autoimmune Antibody Assays
Description: GAD-65, Islet cell-Ab, IA-2 Ab, anti-insulin Ab, and ZnTn8 Ab
Study: NCT06246396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline Hydrochloride
Description: Minocycline Hydrochloride 100 mg twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05988788

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Epigallocatechin-3-gallate
Description: to be used as a root canal irrigant

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: sodium hypochlorite
Description: to be used as a root canal irrigant
Study: NCT05972655

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Modified short-course radiotherapy
Description: radiation targeting the tumor bed without irradiating surrounding tumor-draining lymph nodes: 25Gy/5Fx

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 antibody
Description: PD-1 antibody (Tislelizumab): 200mg d1 q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine: 1000mg/m2 d1-14 q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin: 130mg/m2 d1 q3w
Study: NCT05546866

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Subjects successfully enrolled into the study will receive 80mg osimertinib QD p.o. until completion of planned treatment duration, recurrence of disease, or other treatment discontinuation criteria is met. The maximum treatment duration period is 3 years.
Study: NCT06264986

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ashwagandha
Description: The intervention will be 600mg of KSM-66, a branded supplement derived from the root extract of the herb ashwagandha, with a consistent rate of 5% withanolides for 28 days. It is the most clinically studied extract of the herb and is the only type of ashwagandha to receive third party testing certification (Informed Sport, Informed Ingredient, Banned Substances Control Group, Clean Label Project). The laboratory where the product is made, Ixoreal Biomed, has received Current Good Laboratory Practices (cGLP), quality controlled and tested against heavy metals and pesticides.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 600mg chickpea flour in a hydroxypropyl methylcellulose capsule, once a day for 28 days
Study: NCT05086250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Weekly oral administration of 0.5mg/kg ketamine for 4 weeks, followed by weekly oral administration of placebo for 4 weeks (separated by a washout period of 2 weeks).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Weekly oral administration of 0.5mg/kg ketamine for 4 weeks, followed by weekly oral administration of placebo for 4 weeks (separated by a washout period of 2 weeks).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Weekly oral administration of placebo for 4 weeks, followed by weekly oral administration of 0.5mg/kg ketamine for 4 weeks (separated by a washout period of 2 weeks).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Weekly oral administration of placebo for 4 weeks, followed by weekly oral administration of 0.5mg/kg ketamine for 4 weeks (separated by a washout period of 2 weeks).
Study: NCT06133842

Intervention type: DIAGNOSTIC_TEST
Intervention: Intra-op EEG and CO data collection
Description: Intra-op EEG and CO data will be collected non-invasively. This will not guide or affect patient care of procedure in any way.
Study: NCT05523700

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile Application
Description: Intervention is a mobile application than combines patient data via EMR with PROMIS outcome measures.
Study: NCT05784441

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-90009530
Description: JNJ-90009530, an autologous Chimeric Antigen Receptor (CAR) - T therapy targeting CD20
Study: NCT05651022

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decoy20
Description: Decoy20 is a novel, systemically administered multiple Toll-like receptor (TLR) agonist-based cancer immunotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decoy20
Description: Decoy20 is a novel, systemically administered multiple Toll-like receptor (TLR) agonist-based cancer immunotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decoy20
Description: Decoy20 is a novel, systemically administered multiple Toll-like receptor (TLR) agonist-based cancer immunotherapy.
Study: NCT05651022

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decoy20
Description: Decoy20 is a novel, systemically administered multiple Toll-like receptor (TLR) agonist-based cancer immunotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decoy20
Description: Decoy20 is a novel, systemically administered multiple Toll-like receptor (TLR) agonist-based cancer immunotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decoy20
Description: Decoy20 is a novel, systemically administered multiple Toll-like receptor (TLR) agonist-based cancer immunotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decoy20
Description: Decoy20 is a novel, systemically administered multiple Toll-like receptor (TLR) agonist-based cancer immunotherapy.
Study: NCT06449586

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letermovir
Description: letermovir stops when CMI\>1.5

Intervention type: DRUG
Group type: OTHER
Intervention: Letermovir
Description: letermovir stops when CMI\>1.5
Study: NCT06393114

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fermented oat-based product
Description: Participants will incorporate a novel fermented product into their habitual diet for three weeks. In addition, the consumption of dairy and plant-based dairy alternatives is restricted. Cereal product consumption, specifically bread and porridge, is slightly restricted to prevent gastrointestinal symptoms caused by the increased intake of dietary fibre. Participants will receive dietary guidance on how to follow the intervention diet, as well as potential supplement recommendations provided by the authorized nutritionist.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Unfermented oat-based product
Description: Participants will incorporate a novel unfermented product into their habitual diet for three weeks. Dietary adjustments and other guidance are consistent with those described during the fermented product intervention.
Study: NCT06557850

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AG22515
Description: Solution for infusion
Study: NCT06291246

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Family Navigation
Description: Participants randomized to the Family Navigation condition will receive up to 4 research-based individual sessions with a trained navigator to support them in identifying and enrolling in recommended autism early intervention services. All navigation sessions will be delivered virtually via phone/Zoom.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational Materials
Description: The comparison condition (Educational Materials) consists of providing the participant's caregivers information about early intervention and community-based supports (i.e., infant-toddler programs, transition to school-based supports, family support groups, local organizations. Families in this condition will receive this information throughout 4 timepoints in the first 3 months after enrolling.
Study: NCT05425641

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Feedback on Behavior
Description: Individuals will receive daily text messages that include the Feedback behavior change technique (BCT) with the goal of increasing daily walking by 1,000 more steps than their baseline average step count. An example of the Feedback BCT is Your goal is to walk 1000 steps more than your baseline average. Yesterday you did not meet your goal. If you think this is incorrect you can check your step count from yesterday on your Fitbit app to confirm.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Feedback on Behavior
Description: Individuals will receive daily text messages that include the Feedback behavior change technique (BCT) with the goal of increasing daily walking by 1,000 more steps than their baseline average step count. An example of the Feedback BCT is Your goal is to walk 1000 steps more than your baseline average. Yesterday you did not meet your goal. If you think this is incorrect you can check your step count from yesterday on your Fitbit app to confirm.
Study: NCT05916092

Intervention type: DEVICE
Intervention: TransLoc 3D
Description: TransLoc 3D SI Joint Fusion System

Intervention type: DEVICE
Intervention: TransLoc 3D
Description: TransLoc 3D SI Joint Fusion System
Study: NCT05214313

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music Therapy
Description: The standardised music therapy protocol of 45 minutes will include at each session :~* 10 min of musical listening in a soothing environment (relaxation chair and reduced and coloured lighting) in sensory isolation (with headphones) and aimed at relaxation as a preamble to the active phase of the protocol~* Active phase: (25 min)~* 5 min of receptive music therapy linked to a given emotion, different at each session (joy, sadness, anger and fear) aimed at emotional management (feeling and distancing),~* 20 minutes of active music therapy with instrumental and vocal improvisation that solicits the body physiologically,~* 10 minutes of musical listening in sensory isolation for a state of rest.~The entire protocol is carried out with the permanent perception of heartbeats set to a physiological frequency of 50 to 100 BPM.
Study: NCT06232668

Intervention type: PROCEDURE
Intervention: Chorionic biopsy and peripheral blood collection in cases group
Description: Chorionic villi will be collected from women who have a recommendation for aneuploidy testing, and the remaining fragment will be used for this study and peripheral blood collection in cases group. Clinical data will be compiled.

Intervention type: PROCEDURE
Intervention: Chorionic biopsy and peripheral blood collection in control group
Description: Chorionic villi will be collected from women who have a recommendation for aneuploidy testing, and the remaining fragment will be used for this study and peripheral blood collection in control group. Clinical data will be compiled.
Study: NCT03921944

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: CT scan of the shoulders
Description: studies of both operative and nonoperative shoulders
Study: NCT05020262

Intervention type: OTHER
Intervention: CT Image reconstruction
Description: Retrospectively collects CT Images and reconstruct using PI/PC and Idose4/Cardiac Images to assessment the performance of the two new software functions of Incisive CT. No direct intervention to patients. And ICF is exempted by EC.

Intervention type: OTHER
Intervention: CT Image reconstruction
Description: Retrospectively collects CT Images and reconstruct using PI/PC and Idose4/Cardiac Images to assessment the performance of the two new software functions of Incisive CT. No direct intervention to patients. And ICF is exempted by EC.
Study: NCT04802096

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: inspiratory muscle training
Description: Intensity of inspiratory muscle training will be set at 30% of maximal inspiratory pressure. Subjects in intervention experimental group will perform 15 breaths per set, 6 sets per day on daily basis. The intervention will be last for 8 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pulmonary rehabilitation
Description: Pulmonary rehabilitation consists of aerobic exercise training, strength training, and education related to airway clearance and drug utilization. All of subjects will receive 8-week pulmonary rehabilitation.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: pulmonary rehabilitation
Description: Pulmonary rehabilitation consists of aerobic exercise training, strength training, and education related to airway clearance and drug utilization. All of subjects will receive 8-week pulmonary rehabilitation.
Study: NCT06112223

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Patients will receive oral gabapentin 600 mg 1 hour before the surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol
Description: Patients will receive oral tramadol 100 mg 1 hour before the surgery.
Study: NCT06062459

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motor Control Exercise
Description: Motor control exercises focusing on the activation and control of deep spinal muscles

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motor Control Exercise
Description: Motor control exercises focusing on the activation and control of deep spinal muscles

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balance Training
Description: Balance training exercises on to enhance proprioception and stability

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balance Training
Description: Balance training exercises on to enhance proprioception and stability

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Group
Description: Participants received hot pack and stretching exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Group
Description: Participants received hot pack and stretching exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Group
Description: Participants received hot pack and stretching exercise

Intervention type: OTHER
Group type: OTHER
Intervention: Control Group
Description: Participants received hot pack and stretching exercise
Study: NCT06562634

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: erector spinea plane block
Description: an echogenic 22-G block needle is inserted in-plane to the ultrasound beam in a cranial-to-caudal direction until contact was made with the L4 transverse process. Correct location of the needle tip in the fascial plane deep to erector spinae muscle is confirmed by injecting 0.5-1 ml saline and seeing the fluid lifting the erector spinae muscle off the transverse process while not distending the muscle. A total of 20ml bupivicaine 0.25%, and 20 ml xylocaine 1% will be injected into the ESP on the affected side.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine Sulfate
Description: intravenous morphine will be given in a dose of 0.1-0.2mg/kg to maintain intraoperative analgesia.
Study: NCT04736446

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: I-gel® supraglottic device
Description: Use of an i-gel® supraglottic device to deliver ventilations

Intervention type: DEVICE
Group type: OTHER
Intervention: Face mask ventilation
Description: Use of a face mask to deliver ventilations
Study: NCT04929288

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alcohol
Description: Participants will complete three experimental sessions. In each session, participants will provide detailed reports of their alcohol consumption over the past five days, and they will provide a blood sample for hormone assays. They will perform tasks during fMRI to assess each of the neurofunctional addiction domains: inhibitory control, negative emotionality, and cue reactivity. Following the fMRI scan, subjects will self-administer intravenous alcohol to provide a controlled assessment of pharmacologically-driven alcohol consumption.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alcohol
Description: Participants will complete three experimental sessions. In each session, participants will provide detailed reports of their alcohol consumption over the past five days, and they will provide a blood sample for hormone assays. They will perform tasks during fMRI to assess each of the neurofunctional addiction domains: inhibitory control, negative emotionality, and cue reactivity. Following the fMRI scan, subjects will self-administer intravenous alcohol to provide a controlled assessment of pharmacologically-driven alcohol consumption.